CommercialPrior AuthMedium impact
Magnetic Sphincter Augmentation for the Treatment of Gastroesophageal Reflux Disease (GERD) - (Effective Date - 2026-10-15) 7.01.89
Excellus BlueCross BlueShield·NY · Gastroenterology, General Surgery·Digestive System (Gastroenterology)
Effective date
Oct 15, 2026
We identified it
Jul 16, 2026
Summary
Excellus BlueCross BlueShield has established coverage criteria for Magnetic Sphincter Augmentation (LINX system) for GERD treatment effective October 15, 2026. MSA is now considered medically appropriate when specific clinical criteria are met, including age 18+, BMI <35, documented pathologic acid exposure, failure of 6+ months of optimized PPI therapy, and absence of contraindications. All other uses remain investigational.
Action Required
Before October 15, 2026: Billing and clinical teams must implement prior authorization requirements for MSA procedures. (1) Update billing system to flag MSA claims for prior auth review. (2) Create pre-authorization checklist requiring: patient age verification (18+), BMI documentation (<35 kg/m²), esophageal pH monitoring results, documentation of 6+ months adherence to optimized PPI therapy (both lifestyle modification and maximum/maximally tolerated PPI dosing), and confirmation of hiatal hernia repair status if >2cm present. (3) Establish contraindication screening requiring provider attestation that patient does not have: major esophageal motility disorder, Grade C/D esophagitis, esophageal stricture, esophageal/gastric varices, suspected/confirmed esophageal/gastric cancer, scleroderma, or documented titanium/stainless steel/nickel/iron allergy. (4) Update provider encounter forms and templates to capture all required medical necessity documentation. (5) Train billing staff and providers on the specific approval criteria—claims missing any required element will be denied. (6) Note MRI limitation: device is MR-conditional at 1.5T only; communicate to patients at time of authorization.